W
bioLLM/wiki

AI-Curated Biomedical Knowledge Base

Live
Back to List ViewGraph View

platelet-derived growth factor receptor alpha

Overview

Platelet-derived growth factor receptor alpha (PDGFRα) is a transmembrane receptor tyrosine kinase that plays a critical role in cellular growth, differentiation, and tissue development. As a member of the class III receptor tyrosine kinase family, PDGFRα is activated by platelet-derived growth factors and regulates key signaling pathways including PI3K/AKT and mitogen-activated protein kinase (MAPK) cascades. The protein functions as a critical mediator of mesenchymal and stromal cell proliferation and is involved in normal developmental processes and tissue homeostasis. PDGFRα has become a significant therapeutic target in oncology due to its involvement in multiple cancer types, particularly those driven by gain-of-function mutations. The development of selective tyrosine kinase inhibitors targeting PDGFRα has established new treatment paradigms for otherwise difficult-to-treat malignancies.

Recent Publications Summary

Recent research has focused on platelet-derived growth factor receptor alpha (PDGFRA) as a therapeutic target in gastrointestinal stromal tumors (GIST), where PDGFRA mutations are present in approximately 10–15% of cases and confer responsiveness to tyrosine kinase inhibitor therapy 42203307May. Structure-based drug design efforts have been directed toward overcoming oncogenic PDGFRA mutations associated with drug resistance; computational and structural studies identified selective tyrosine kinase inhibitors with 6,7-quinazoline scaffolds that demonstrate high potency against clinically relevant PDGFRA mutations, including the imatinib-resistant D842V variant and the solvent-front PDGFRA-G680R mutation 42562826Aug. In clinical evaluation, avapritinib, a selective PDGFRA inhibitor approved for advanced PDGFRA exon 18-mutant GIST, showed marked pathologic responses in the preoperative setting for localized disease; in an exploratory case series of eight patients with localized PDGFRA-mutant gastric GIST, seven experienced tumor size reduction (median 25%), and five undergoing surgical resection achieved complete or near-complete pathologic response (≤5% viable tumor) 42528110Jul.

Beyond GIST, PDGFRA has been investigated as a therapeutic target in other disease contexts. A PDGFRα-targeted cell membrane-camouflaged nanotherapy was developed to address intervertebral disc degeneration (IVDD) by disrupting fibrosis-inflammation coupling; the approach targeted pathogenic nucleus pulposus cell populations characterized by concurrent activation of extracellular matrix remodeling and inflammatory programs 42426566Jul. Computational screening studies have also identified PDGFRA among the core potential targets of phytochemical compounds for lung cancer, with molecular dynamics simulations demonstrating conserved binding interactions at the receptor 42149884May.

What Changes, What Holds

1. Preoperative avapritinib achieves complete or near-complete pathologic response in PDGFRA-mutant GIST
REINFORCES Avapritinib's pathologic responses in the preoperative setting confirm that PDGFRA-targeted kinase inhibition remains effective in GIST, as the Overview establishes. Neoadjuvant application enables substantial therapeutic response in localized disease, demonstrating a specific clinical timing for the established therapeutic paradigm rather than a fundamental shift in how PDGFRα inhibition functions 42528110Jul.

2. PDGFRα inhibition disrupts fibrosis-inflammation coupling in intervertebral disc degeneration
NEW DIRECTION PDGFRA's therapeutic role expands beyond cancer into degenerative musculoskeletal disease, where it disrupts fibrosis-inflammation coupling—a mechanism absent from the Overview's cancer-focused account. IVDD represents an entirely new disease category and therapeutic context. While computational screening concurrently identified PDGFRA as a potential target in lung cancer, the degenerative-disease application marks the substantive departure 42426566Jul.

Overview update candidates: PDGFRA's therapeutic potential in non-malignant diseases; particularly intervertebral disc degeneration.

⚠️ Content is generated using Large Language Models (LLMs) and may contain errors or hallucinations. Experts periodically review it to verify accuracy and maintain database integrity.